TP53 mutational status is predictive of pazopanib response in advanced sarcomas.

@article{Koehler2016TP53MS,
  title={TP53 mutational status is predictive of pazopanib response in advanced sarcomas.},
  author={Kevin A Koehler and Diana Liebner and James L. Chen},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2016},
  volume={27 3},
  pages={
          539-43
        }
}
BACKGROUND To investigate whether TP53 DNA mutational status impacts progression-free survival (PFS) in patients with advanced sarcomas (soft tissue sarcoma) treated with vascular endothelial growth factor receptors (VEGFR) inhibition. PATIENTS AND METHODS We retrospectively reviewed 19 cases of patients treated at the Ohio State James Comprehensive Cancer Center with advanced sarcoma treated with VEGFR inhibition who also had next-generation sequencing of their tumors (via FoundationOne Heme… CONTINUE READING
BETA

Figures, Tables, and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 15 CITATIONS

Liquid biopsies for hepatocellular carcinoma.

  • Translational research : the journal of laboratory and clinical medicine
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 14 REFERENCES

Post marketing surveillance in Japan for soft tissue sarcoma patients treated with pazopanib. Abstract 3438

A. Kawai
  • In European Cancer Congress
  • 2015
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…